Zepp Health's Q3 revenue surges 78.5% on product launches

Zepp Health

05/11/2025 01:42

Overview

Zepp Health Q3 revenue grew 78.5% yr/yr, driven by new product launches

The fitness wearables supplier achieved adjusted operating income breakeven, marking milestone towards profitability

Zepp Health's cash position strengthened in the quarter, with cash balance increasing to $102.6 mln

Outlook

Zepp Health expects Q4 2025 revenue between $82 mln and $86 mln

Company anticipates cash balance growth in Q4 2025

Zepp Health's forecast reflects continued profitability improvement and favorable product mix

Result Drivers

NEW PRODUCT LAUNCHES - Revenue growth driven by new products, especially Amazfit T-Rex 3 Pro

GROSS MARGIN IMPROVEMENT - Improved product mix and new launches boosted gross margin

SUPPLY CONSTRAINTS AND TYPHOON - Sales impacted by supply issues and end-of-quarter typhoon

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Gross Margin
38.2%


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the phones & handheld devices peer group is "buy"

Wall Street's median 12-month price target for Zepp Health Corp is $59.76, about 38% above its November 4 closing price of $37.07

Press Release: ID:nPnccjZCka

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)